

## LRP5

**Reactivity:** Human Mouse Rat

**Tested applications:** WB IHC

**Recommended Dilution:** WB 1:500 - 1:2000 IHC 1:50 - 1:200

**Calculated MW:** 179kDa

**Observed MW:** Refer to Figures

**Immunogen:**

Recombinant protein of human LRP5

**Storage Buffer:**

Store at -20. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

**Synonym:**

LRP5;BMND1;EVR1;EVR4;HBM;LR3;LRP7;OPPG;OPS;OPTA1;VBCH2;

**Catalog #:** A0130

**Antibody Type:**

Polyclonal Antibody

**Species:** Rabbit

**Gene ID:** 4041

**Isotype:** IgG

**Swiss Prot:** O75197

**Purity:** Affinity purification

For research use only.

**Background:**

LRP5 and LRP6 are single-pass transmembrane proteins belonging to the low-density lipoprotein receptor (LDLR)-related protein family. Unlike other members of the LDLR family, LRP5 and LRP6 have four EGF and three LDLR repeats in the extracellular domain, and proline-rich motifs in the cytoplasmic domain (1). They function as co-receptors for Wnt and are required for the canonical Wnt/-catenin signaling pathway (2,3). LRP5 and LRP6 are highly homologous and have redundant roles during development (4,5). The activity of LRP5 and LRP6 can be inhibited by the binding of some members of the Dickkopf (DKK) family of proteins (6,7). Upon stimulation with Wnt, LRP6 is phosphorylated at multiple sites including Thr1479, Ser1490, and Thr1493 by kinases such as GSK-3 and CK1 (8-10). Phosphorylated LRP6 recruits axin to the membrane and presumably activates -catenin signaling (8-10). LRP5 is involved in the regulation of bone homeostasis. Mutations and polymorphisms in LRP5 are associated with bone diseases like osteoporosis-pseudoglioma syndrome and high-bone-mass disorders (11-13). In addition, mutations in LRP5 are found in patients with hyperparathyroid tumor and breast cancer (14,15).

**To place an order, please [Click HERE](#).**